Dapagliflozin Improves Glycemic Control and Reduces Body Weight as Add-on Therapy to Metformin Plus Sulfonylurea: A 24-Week Randomized, Double-Blind Clinical Trial
| Autor: | Stephan Matthaei, Shamik Parikh, Keith Bowering, K Rohwedder, Anke Grohl |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Blood Glucose
Male medicine.medical_specialty medicine.drug_class Endocrinology Diabetes and Metabolism Urology Blood Pressure Type 2 diabetes Hypoglycemia Placebo chemistry.chemical_compound Double-Blind Method Glucosides Internal medicine Diabetes mellitus Internal Medicine medicine Humans Hypoglycemic Agents Benzhydryl Compounds Dapagliflozin Aged Glycemic Advanced and Specialized Nursing business.industry Body Weight Middle Aged medicine.disease Sulfonylurea Metformin Sulfonylurea Compounds Endocrinology Diabetes Mellitus Type 2 chemistry Urinary Tract Infections Drug Therapy Combination Female business medicine.drug |
| Zdroj: | Diabetes Care. 38:365-372 |
| ISSN: | 1935-5548 0149-5992 |
| Popis: | OBJECTIVE To evaluate the efficacy and safety of dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin and sulfonylurea. RESEARCH DESIGN AND METHODS Patients with HbA1c of 7.0% (53 mmol/mol) to 10.5% (91 mmol/mol) receiving sulfonylurea and metformin were randomized to receive dapagliflozin 10 mg/day (n = 109) or placebo (n = 109) for 24 weeks. RESULTS HbA1c (baseline: dapagliflozin 8.08% [65 mmol/mol]; placebo 8.24% [67 mmol/mol]) and fasting plasma glucose (baseline: dapagliflozin 167.4 mg/dL [9.29 mmol/L]; placebo 180.5 mg/dL [10.02 mmol/L]) significantly improved from baseline with dapagliflozin (placebo-subtracted change –0.69% [–7.5 mmol/mol], P < 0.0001; –33.5 mg/dL [–1.86 mmol/L], P < 0.0001, respectively). More patients achieved a therapeutic glycemic response (HbA1c CONCLUSIONS Dapagliflozin was well tolerated and effective over 24 weeks as add-on to metformin plus sulfonylurea. Adverse effects included hypoglycemia and genital infections. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|